Investor Presentaiton

Investor presentation Full year 2018 Slide 108 Solid operating profit growth driven by diabetes Operating profit DKK billion Operating profit Operating profit as % of sales Reported operating profit growth Operating profit split per franchise Diabetes care and obesity Biopharm 60 60 Operating profit growth in local currencies 60% 50 50% 26% 20% 40 40% 30 30% 74% 80% 20 20% 10% 35% 4% 1% -4% 10 10% 13% 13% 6% 5% 3% 0 0% 2014 2015* 2016* 2017 2018 2014 2018 * Adjusted for the partial divestment of NNIT A/S and inflammatory out-licensing in 2015 changing diabetes novo nordisk

View entire presentation